All In Biotech

Drug Trial Radar · NCT03960580

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID) in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

Last checked: Nov 19, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 223 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

223

Actual

Start

Jun 6, 2019

Primary completion

May 4, 2022

Study completion May 4, 2022

Sponsor

Lead sponsor
Optinose US Inc.Industry
Sponsor type
Industry
First posted
May 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of intranasal administration of 186 and 372 μg twice daily (BID) of OPN-375 in subjects with chronic Rhinosinusitis (CRS) without nasal polyps

Conditions

  • Chronic Rhinosinusitis

Interventions

  • OPN-375Drug

    OPN-375, BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior and/or Posterior) at the End of Week 4Time frame: 4 Weeks
  2. Change From Baseline to Week 24/Early Termination (ET) in the Average Percent of the Volume Opacified (APOV) in the Ethmoid and Maxillary Sinuses.Time frame: Baseline, Week 24

Locations

87 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Sacramento Ear, Nose & Throat Surgical and Medical Group Inc

    Folsom, California

  • BioSolutions Clinical Research Center

    La Mesa, California

  • Veterans Administration Greater Los Angeles Healthcare System

    Los Angeles, California

  • Sacramento Ear, Nose & Throat Surgical and Medical Group

    Roseville, California

  • Asthma and Allergy Associates

    Colorado Springs, Colorado

  • Sher Allergy Specialists

    Largo, Florida

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Treasure Valley Medical Research

    Boise, Idaho

  • Best Clinical Trials

    New Orleans, Louisiana

  • University of Missouri, Dept of Otorlaryngology

    Columbia, Missouri

  • Mount Sinai Downtown Union Square

    New York, New York

  • Northwell Health at ENT and Allergy Associates

    New York, New York

  • Charlotte Eye Ear Nose and Throat Assoc., PA

    Matthews, North Carolina

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • ENT & Allergy Partners, LLC

    Summerville, South Carolina

  • Pasha Snoring & Sinus Center

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • Eastern Virginia Medical School

    Norfolk, Virginia

  • Allergy, Asthma & Sinus Center, SC

    Greenfield, Wisconsin

  • Otopure Pty Ltd

    Bella Vista, New South Wales, Australia

  • Vale Medical Practice

    Brookvale, New South Wales, Australia

  • Australian Clinical Research Network

    Maroubra, New South Wales, Australia

  • Browns Plains Family Practice

    Browns Plains, Queensland, Australia

  • Casey Superclinic

    Berwick, Victoria, Australia

  • Camberwell Road Medical Practice

    Hawthorn East, Victoria, Australia

  • Mirrabooka Medical Centre

    Mirrabooka, Western Australia, Australia

  • Latitude Clinical Research

    Spearwood, Western Australia, Australia

  • UMHAT Kaspela EOOD

    Plovdiv, Bulgaria

  • Medical Center Iskar EOOD

    Sofia, Bulgaria

  • MHAT Serdika EOOD

    Sofia, Bulgaria

  • MC N.I. Pirogov EOOD

    Sofia, Bulgaria

  • MHAT - Central Clinical Base Sofia Medical Institute Ministry of Interior

    Sofia, Bulgaria

  • MMA MHAT - Sofia

    Sofia, Bulgaria

  • DCC Convex EOOD

    Sofia, Bulgaria

  • MHAT Trakiya EOOD

    Stara Zagora, Bulgaria

  • DCC "Mladost - M Varna" OOD

    Varna, Bulgaria

  • Nemocnice Rudolfa a Stefanie Benesov, a.s., ORL oddeleni

    Benešov, Czechia

  • FN Hradec Kralove, Klinika ORL

    Hradec Králové, Czechia

  • Pro-audio s.r.o.

    Mladá Boleslav, Czechia

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.